We are live on ! Find out more
CTMX icon

CytomX Therapeutics
CTMX

86 hedge funds and large institutions have $332M invested in CytomX Therapeutics in 2017 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 29 increasing their positions, 20 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

800% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 3

300% more funds holding in top 10

Funds holding in top 10: 1 → 4 (+3)

79% more capital invested

Capital invested by funds: $185M → $332M (+$146M)

45% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 20

26% more funds holding

Funds holding: 68 → 86 (+18)

6.08% more ownership

Funds ownership: 46.31% → 52.39% (+6.1%)

Holders
86
Holders Change
+18
Holders Change %
+26.47%
% of All Funds
2.14%
Holding in Top 10
4
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+300%
% of All Funds
0.1%
New
27
Increased
29
Reduced
20
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BI
BVF Inc
California
+$16.4M
2
BlackRock
BlackRock
New York
+$13.2M
3
EC
EcoR1 Capital
California
+$10.5M
4
PA
Perceptive Advisors
New York
+$7.99M
5
DCM
Driehaus Capital Management
Illinois
+$3.88M

Top Sellers

Rank Fund Capital Flow
1
PI
Putnam Investments
Massachusetts
-$17M
2
VMI
VHCP Management II
New York
-$3.8M
3
TCM
Tekla Capital Management
Massachusetts
-$2.97M
4
CAM
Cormorant Asset Management
Massachusetts
-$1.86M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$696K
Name Holding Trade Value Shares
Change 		Change in
Stake
Canada Life
76
Canada Life
Manitoba, Canada
$31K – – –
AIP
77
Ameritas Investment Partners
Nebraska
$27K +$20.9K +1,591 New
Fifth Third Bancorp
78
Fifth Third Bancorp
Ohio
$26K – – –
AIM
79
Acrospire Investment Management
Illinois
$25K +$18.9K +1,437 New
Royal Bank of Canada
80
Royal Bank of Canada
Ontario, Canada
$13K -$1.79K -136 -16%
Citigroup
81
Citigroup
New York
$8K -$266K -20,201 -98%
MAM
82
Meeder Asset Management
Ohio
$5K -$3.46K -263 -49%
TRCT
83
Tower Research Capital (TRC)
New York
$5K +$3.8K +289 New
BNP Paribas Financial Markets
84
BNP Paribas Financial Markets
France
$4.14K -$12.9K -978 -80%
AWMS
85
Advocacy Wealth Management Services
Georgia
$2K +$1.32K +100 New
FMA
86
FNY Managed Accounts
New York
$2K +$2.12K +161 New
PAM
87
Panagora Asset Management
Massachusetts
$1K +$737 +56 New
Susquehanna International Group
88
Susquehanna International Group
Pennsylvania
– -$365K -33,186 Closed
Squarepoint
89
Squarepoint
New York
– -$180K -16,360 Closed
CS
90
Credit Suisse
Switzerland
– -$139K -12,735 Closed
1 2 3
4

CTMX Hedge Fund Activity: Q1 2017 in Review

86 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q1 2017, worth a combined $332M — up 79% from $185M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new CTMX positions and 3 closed out — a net gain of 24 holders — while 29 added to existing stakes and 20 trimmed.

The largest buyer was BVF Inc, adding an estimated $16.4M. The largest seller was Putnam Investments, cutting an estimated $17M.

  • 86 institutional investors held CytomX Therapeutics (CTMX) as of Q1 2017, up from 68 in Q4 2016.
  • Funds reported $332M of CytomX Therapeutics stock for Q1 2017, up 79% quarter-over-quarter.
  • 27 funds opened new CytomX Therapeutics positions in Q1 2017 and 3 closed out, a net change of +24 holders.
  • The largest CytomX Therapeutics buyer in Q1 2017 was BVF Inc, an estimated $16.4M added.
  • The largest CytomX Therapeutics seller in Q1 2017 was Putnam Investments, an estimated $17M sold.

Based on aggregated 13F filings for Q1 2017.